FDA Proposes Curbs on Mass Copycats of Novo, Lilly’s Weight-Loss DrugsFDA Proposes Curbs on Mass Copycats of Novo, Lilly’s Weight-Loss DrugsFDA Proposes Curbs on Mass Copycats of Novo, Lilly’s Weight-Loss Drugs 

USA TODAY Network / ReutersThe Food and Drug Administration on April 30 proposed excluding Novo Nordisk and Eli Lilly’s weight-loss drugs from a key compounding list, potentially limiting large-scale production by outsourcing facilities. If finalized, the move could impact telehealth firms that rely on outsourcing facilities to produce these drugs in bulk, while bolstering Novo and Lilly’s efforts against unauthorized…